Each dot is one of the 63 Biotechnology stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 22.3% and the median P/E 16.31. Pinned to the edge: 7 outliers on X and 4 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 45.5% | 46.74 | $1.36T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 42.83 | $688.76B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.7% | 50.48 | $521.69B | Pharmaceuticals |
| 4 | MRKMerck | 4.9% | 148.68OUT | $364.31B | Pharmaceuticals |
| 5 | AZNAstrazeneca | 7.8% | 25.92 | $285.96B | Pharmaceuticals |
| 6 | AMGNAmgen | 8.2% | 26.83 | $251.88B | Biotechnology |
| 7 | VRTXVertex Pharmaceuticals | 10.5% | 34.34 | $136.55B | Biotechnology |
| 8 | BMYBristol Myers Squibb | 4.2% | 14.02 | $129.66B | Pharmaceuticals |
| 9 | GSKGsk | 82.9% | 8.11 | $108.86B | Pharmaceuticals |
| 10 | REGNRegeneron Pharmaceuticals | 18.6% | 20.17 | $97.17B | Biotechnology |
| 11 | ARGXArgenx Se | 61.5% | 31.35 | $59.41B | Biotechnology |
| 12 | SNYSanofi | -19.6% | 6.24 | $58.98B | Pharmaceuticals |
| 13 | TEVATeva Pharmaceutical Industries | 2.7% | 102.64 | $51.97B | Generic Drugs |
| 14 | ONCBeOne Medicines | 32.9% | 51.73 | $47.53B | Pharmaceuticals |
| 15 | BIIBBiogen | 2.3% | 107.78 | $37.46B | Biotechnology |
| 16 | ALNYAlnylam Pharmaceuticals | 60.8% | 8.34 | $22.09B | Biotechnology |
| 17 | ZBHZimmer Biomet Holdings | 7.0% | 25.63 | $19.53B | Medical Devices |
| 18 | ASNDAscendis Pharma A | 93.8% | 16.31 | $17.07B | Biotechnology |
| 19 | NBIXNeurocrine Biosciences | 38.0% | 24.21 | $16.96B | Pharmaceuticals |
| 20 | EXELExelixis | 9.1% | 19.24 | $16.88B | Pharmaceuticals |
| 21 | KNSAKiniksa Pharmaceuticals International | 58.2% | 68.75 | $15.13B | Biotechnology |
| 22 | RDYDr Reddys Laboratories | -10.5% | 33.78 | $12.31B | Generic Drugs |
| 23 | HALOHalozyme Therapeutics | 45.0% | 23.51 | $11.42B | Biotechnology |
| 24 | TGTXTg Therapeutics | 68.8% | 85.63 | $9.75B | Biotechnology |
| 25 | GMEDGlobus Medical | 13.4% | 17.35 | $9.56B | Medical Devices |
| 26 | PTGXProtagonist Therapeutics | 163.7% | 25.39 | $8.54B | Biotechnology |
| 27 | LGNDLigand Pharmaceuticals | 1.0% | 119.78OUT | $6.18B | Biotechnology |
| 28 | ARQTArcutis Biotherapeutics | 60.0% | 123.78OUT | $3.56B | Biotechnology |
| 29 | TAKTakeda Pharmaceutical | -35.4% | 10.69 | $3.41B | Pharmaceuticals |
| 30 | GMABGenmab A | 22.5% | 3.81 | $3.30B | Biotechnology |
| 31 | ADMAAdma Biologics | 6.3% | 16.78 | $3.05B | Biotechnology |
| 32 | LKFTLakefront Biotherapeutics | 240.8%OUT | 2.40 | $2.24B | Biotechnology |
| 33 | AUPHAurinia Pharmaceuticals | 21.0% | 6.68 | $2.11B | Pharmaceuticals |
| 34 | HRMYHarmony Biosciences Holdings | 19.8% | 11.04 | $1.98B | Pharmaceuticals |
| 35 | ZYMEZymeworks | 97.8% | 43.39 | $1.87B | Biotechnology |
| 36 | NRIXNurix Therapeutics | 738.8%OUT | 5.86 | $1.69B | Biotechnology |
| 37 | JAZZJazz Pharmaceuticals | 13.5% | 7.59 | $1.55B | Pharmaceuticals |
| 38 | ANABAnaptysbio | 41.9% | 87.82 | $1.38B | Biotechnology |
| 39 | PHARPharming | -6.5% | 35.82 | $884.12M | Biotechnology |
| 40 | RIGLRigel Pharmaceuticals | 2.2% | 2.71 | $837.18M | Biotechnology |
| 41 | ABUSArbutus Biopharma | 1,143%OUT | 3.70 | $812.59M | Biotechnology |
| 42 | IRWDIronwood Pharmaceuticals | 18.1% | 5.32 | $799.61M | Biotechnology |
| 43 | ZVRAZevra Therapeutics | 75.2% | 6.91 | $539.71M | Pharmaceuticals |
| 44 | KMDAKamada | 12.6% | 19.04 | $466.68M | Biotechnology |
| 45 | AGENAgenus | 25.4% | 14.31 | $421.62M | Biotechnology |
| 46 | PBYIPuma Biotechnology | 9.4% | 16.86 | $401.70M | Biotechnology |
| 47 | CRMDCorMedix | 92.5% | 5.90 | $370.36M | Pharmaceuticals |
| 48 | ALECAlector | 151.2% | 6.86 | $285.18M | Biotechnology |
| 49 | QTTBQ32 Bio | 75.7% | 120.37OUT | $260.36M | Biotechnology |
| 50 | INCYIncyte | 24.9% | 0.61 | $246.78M | Pharmaceuticals |
| 51 | PLXProtalix BioTherapeutics | 37.0% | 11.87 | $245.74M | Biotechnology |
| 52 | OMEROmeros | 1,532%OUT | 2.25 | $236.99M | Biotechnology |
| 53 | CGENCompugen | 1,000.0%OUT | 5.39 | $198.56M | Biotechnology |
| 54 | FHTXFoghorn Therapeutics | 357.3%OUT | 15.73 | $124.12M | Biotechnology |
| 55 | VXRTVaxart | 22.3% | 3.01 | $87.73M | Biotechnology |
| 56 | RLYBRallybio | -35.6% | 3.35 | $83.84M | Biotechnology |
| 57 | FBIOFortress Biotech | 12.3% | 0.65 | $62.62M | Biotechnology |
| 58 | ATNMActinium Pharmaceuticals | 936.3%OUT | 4.55 | $51.56M | Biotechnology |
| 59 | IBOImpact Biomedical | 22.6% | 27.21 | $43.92M | Biotechnology |
| 60 | KYNBKyntra Bio | 3.0% | 0.08 | $13.93M | Biotechnology |
| 61 | OTLCOncotelic Therapeutics | 36.5% | 0.02 | $4.57M | Biotechnology |
| 62 | OSRHOSR Health | -50.4% | 0.71 | $3.51M | Biotechnology |
| 63 | PTIXProtagenic Therapeutics, Inc.new | -43.1% | 0.15 | $850.80K | Biotechnology |
Among Biotechnology stocks, the largest companies growing revenue faster than the median (22.3%) while trading below the median P/E (16.31) are Gsk (GSK), Alnylam Pharmaceuticals (ALNY), Genmab A (GMAB), Lakefront Biotherapeutics (LKFT) and Nurix Therapeutics (NRIX). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Astrazeneca (AZN) and Amgen (AMGN).
The median P/E across the 63 Biotechnology stocks plotted is 16.31, with the middle half between 5.63 and 34.06.
The median is 22.3%, with the middle half between 7.4% and 65.2%.
The rank correlation (Spearman) is -0.08, a no meaningful negative relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 7 companies are outliers on Revenue Growth (1y) (TTM) and 4 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.